Compound Preferred LLC, Idaho Falls, ID
Is Compound Preferred LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.
Does Compound Preferred LLC hold a Idaho pharmacy license?
State board of pharmacy records for Idaho are not checked: the board’s former web address (bop.idaho.gov) did not respond on November 6, 2026, and no longer resolved when tried again on November 7, 2026; the board’s pages now sit on the Division of Occupational and Professional Licenses site, which this index has not yet read. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054022133 for COMPOUND PREFERRED LLC, IDAHO FALLS, ID, status CLOSED, as of Nov 13, 2026.
Has Compound Preferred LLC had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 2 Form 483s (Aug 1, 2019 and Dec 17, 2021) for Compound Preferred LLC. State board of pharmacy records for Idaho are not checked: the board’s former web address (bop.idaho.gov) did not respond on November 6, 2026, and no longer resolved when tried again on November 7, 2026; the board’s pages now sit on the Division of Occupational and Professional Licenses site, which this index has not yet read.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Compound Preferred LLC
- Location
- Idaho Falls, ID
- Type as FDA labels it
- 503B
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Dec 17, 2021
- FDA Data Dashboard inspections
- 2 inspections: 2 OAI; 3 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 27 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Compound Preferred LLC, a 503B facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Dec 17, 2021 | Form 483 | 483 Issued 12/17/2021 | fda.gov |
| Aug 1, 2019 | Form 483 | 483 Issued 08/01/2019 | Not linked by FDA |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Compound Preferred LLC, Idaho Falls, ID (FEI number 3012465222), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Dec 17, 2021 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3012465222 | 1159061 |
| Mar 1, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3012465222 | 1005663 |
Form 483s FDA has published for this site
- Dec 17, 2021: Form 483 to Compound Preferred LLC, published Oct 19, 2022. fda.gov
- Aug 1, 2019: Form 483 to Compound Preferred LLC, published Oct 18, 2019. fda.gov
- Nov 28, 2017: Form 483 to Compound Preferred LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 27 numbered observations in all, across 3 inspections ending Feb 7, 2017 to Dec 17, 2021. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Nov 9, 2021 to Dec 17, 2021: 7 observations
- Firm on the cover
- Compound Preferred LLC, 1125 Hollipark Dr ., Idaho Falls, ID 83401
- FEI number
- 3012465222
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 22215 26th Ave SE Suite 210 Bothell, WA 98021
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in the ISO 5 classified aseptic processing area during aseptic production.
Your investigations are inadequate in that corrective actions do not address the root cause in nonconformances. Specifically,
A) Viable count excursions:
1) The Quality Unit opened non-conformances (NC) for each of the thirteen (13) personnel monitoring excursions observed between 08/02/2019 to 11/08/2021 in the ISO 5 and ISO 7 classified areas. However, an adequate root cause, and corrective and preventive action to address the nine (9) non-conformances related to the detection of spore forming microorganisms was not determined. Instead, as a corrective action, the Quality Unit decided to relax the Action Limit for fingertip glove sampling and increase the Action Limit from <Redacted B4> CFU to <Redacted B4> CFUs. In addition, SOP 08-004, "Environmental Monitoring and Personnel Monitoring", Revision 12, Effective Date: 10/15/2021 was implemented to reflect this change. ...
Observation 2
Laboratory controls do not include the establishment of scientifically sound and appropriate standards designed to assure that drug product containers conform to appropriate standards of identity, strength, quality and purity.
Specifically, your firm does not the follow manufacturer's test instructions while performing the Endotoxin, <Redacted B4> test for your compounded drug products.
For example, on 11/17/2021, we observed Endotoxin testing being conducted for Procaine (1 % ) HCl 10mg/mL Injection Solution 30mL MDV, Lot <Redacted B4>, produced on 11/16/2021. During the endotoxin test we observed that your firm failed to:
A. Perform he Endotoxin Control Series <Redacted B4>. Your firm only performs <Redacted B4> and does not perform <Redacted B4> per the manufacturer's instructions.
_____________ ___________________ B.
<Red acted B4> for testing.
C. You have not performed any endotoxin <Redacted B4> to rule out the potential of <Redacted B4> by your compounded products.
D. Your fnm has not calculated the <Redacted B4> for any of your compounded products. Per the manufacturer's instructions, the <Redacted B4> method should be validated at a <Redacted B4>.
E. ...
Observation 3
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
A) A review of your firm's personnel and environmental monitoring non-conformances observed between 08/02/2019 to 11/08/2021 show there were thirteen (13) viable growth excursions in the ISO 5 and 7 classified areas. Nine (9) viable growth excursions out of these thirteen (13) were caused due to the detection of spore forming microorganisms. The Quality Unit failed to take adequate actions to address the presence of spore forming organisms in the classified areas and continued the practice of using a sporicidal agent <Redacted B4> per your firm's SOP 05-001, "Cleanroom Suite Cleaning and Sanitizing" Rev. 3, Effective Date: 7/21/2021.
B) On 11/16/2021 during the production of Procaine 1 %, Lot <Redacted B4> we observed the bottom of <Redacted B4> used to move components and items into the clean room were not disinfected with either <Redacted B4> or a sporicidal agent. These <Redacted B4> were placed on a work bench alongside a cardboard box while collecting supplies for aseptic processing. ...
Observation 4
The flow of components, drug product containers, closures and in-process materials through the building is not designed to prevent contamination.
Specifically,
A) On 11/1 6/2021, we observed a compounding technician getting ready for sterile drug compounding operations. <Redacted B4> first removed, <Redacted B4> street clothing and donned a clean pair of surgical scrubs, a clean pair of socks and rubber clogs and a clean pair of non-sterile gloves. Then instead of going directly to the ISO 5 / ISO 7 classified areas '" <Redacted B4> began collecting supplies needed for sterile drug compounding such as sterilized gowns, face hoods and <Redacted B4> particle counter head. The supplies were stored inl <Redacted B4> in an unclassified storage <Redacted B4>. We observed <Redacted B4> clean surgical scrubs come in direct contact with the <Redacted B4>. Wearing the same surgical scrubs, the compounding technician then entered the ISO 8 classified gowning area and started donning the sterile gown over the surgical scrubs to prepare for aseptic operations. ...
Observation 5
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Specifically, since the previous FDA inspection conducted in August of 2019, your firm has not performed any dynamic smoke studies that fully simulate sterile drug production activities in your ISO 5 hoods located in the ISO 7 clean room.
During the cunent inspection, we reviewed the most recent smoke studies performed in March of 2021 at your firm. The smoke studies were conducted only under static conditions. No dynamic studies were performed that showed:
A) The entire filling process, including the priming of the pump used to fill the vials with the compounded drug product.
B) The practice of <Redacted B4> operators working together in your ISO 5 classified hood during filling and capping operations.
The ISO 5 classified hood is used for <Redacted B4> operations at your facility, including the aseptic filling of Procaine (1 % ) HCl 10mg/mL Injection Solution 30mL MDV, <Redacted B4> on 11/16/2021. ...
Observation 6
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically,
A) On 11/16/2021, <Redacted B4> which directly connects the ISO 7 clean room with the unclassified Product Release Room 7, was not cleaned and disinfected prior to the start of filling operations for Procaine 1 %, Lot <Redacted B4> in the ISO 5 classified hood, located in the ISO 7 clean room. Your SOP 05-001 "Cleanroom Suite Cleaning and Sanitizing", Effective Date, 07/21/2021, Rev. 3, Section 3.2.5, states <Redacted B4> however, the SOP does not specify when the <Redacted B4> be cleaned (before or after the sterile drug production). -
B) On 11/12/2021, during our walkthrough of your facility we observed <Redacted B4> vials of "Methylcobalamin 5mg/mL, Injection Solution, Lot <Redacted B4> 30 mL MDV, Exp Date:0 1/10/2020, Prep Date: 10/12/2021" stored on the top shelf of Refrigerator <Redacted B4> in the Product Release Room 7. Your firm's management stated Refngerator <Redacted B4> was empty, unmonitored, and out of service. ...
Observation 7
Routine calibration of automatic and mechanical equipment is not performed according to a written program designed to assure proper performance.
Specifically, on 11/16/2021 after aseptic filling operations of Procaine (1 %) HCl l0mg/mL Injection Solution 30mL MDV, Lot <Redacted B4>, your firm used an uncalibrated <Redacted B4> to conduct the <Redacted B4> testing for confirming the <Redacted B4>
According to your firm's management an uncalibrated <Redacted B4> was used from 08/02/2019 to 08/12/2021, and au uncalibrated <Redacted B4> was used from 08/13/2021 to 11/19/2021 for <Redacted B4> testing. In addition, the firm's management also stated there are no written procedures to assure routine calibration of the <Redacted B4>
There is no assurance that while using these uncalibrated <Redacted B4> the readings obtained during the <Redacted B4> testing are accurate for <Redacted B4> lots of sterile compounded products produced since 08/02/2019.
This is a repeat observation from the FDA inspection conducted in March of 2017.
Inspection Jul 16, 2019 to Aug 1, 2019: 7 observations
- Firm on the cover
- RAM Pharma, Inc, 1125 Hollipark Dr, Idaho Falls, ID 83401
- FEI number
- 3012465222
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- DISTRICT ADDRESS AND PHONE NUMIIER 22215 26th Ave SE Suite 210 Bothell, WA 98021
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard, actions page
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A) On 07/18/2019 during the production of <Redacted B4> 2mg/0.05ml for Injection, the "Pharmacist in Charge" was observed taking a fingertip sample from a gloved hand that was still wet following disinfection with sterile <Redacted B4> before production began.
B) During review of your "Finished Product Sterility Testing" records which includes both environmental and personnel monitoring data from l l/30/2017-05/13/2019, approximately l:J samples taken from inside the ISOS LAFH were positive for growth. For example:
I) 11/30/2017 touch plate was positive for growth.
2) 12/04/2017 settling plate was positive for growth.
3) 06/11/2018 touch plate was positive for growth.
4) 08/17/2018 settling plate was positive for growth.
5) 10/19/2018 (positive for growth, plate type not identified)
No action was taken per SOP 08-004 "Environmental Monitoring-Microbial" and no alert level is established to prevent the possible contamination of sterile drug products (This is a repeat observation from a previous inspection). ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.
' Specifically,
A) SOP 11-006 <Redacted B4> Validation" was updated and implemented on 07/02/2019 to include a biological indicator. However, there is no documentation to establish load mapping studies have been conducted.
B) Your firm has not validated any depyrogenation process for sterile glassware used in the production of "High-Risk" sterile drug products.
C) Your firm is using preservatives for sterile products produced as " multi dose". However, there is no data to establish products using said preservatives have been tested to demonstrate efficacy. (This is a repeat observation from a previous inspection).
Observation 3
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
Specifically,
On 07/18/2019 during the production of <Redacted B4> 2mg/0.05mL for Injection, I observed the use of sterile wipes rendered non-sterile having been left open on top of the LAFH for an unknown period prior to production. These wipes were subsequently used to clean inside the ISOS zone and to clean equipment introduced into the ISOS zone throughout production.
Observation 4
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically,
All stability data for your sterile products was requested in support of extended "Beyond Use Dates" used at your firm . Provided were "Technical Reports" which your firm established to support the use of extended BUD's.
A) Data provided supports sterility testing; no potency testing was conducted.
B) Accelerated studies were either not conducted or data not provided that demonstrates there are no degradant products formed or potency altered under such conditions.
C) Not all products have data to support the use of extended BUD's.
Observation 5
Each batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance to such requirements.
Specifically,
All finished sterile drug products reviewed undergo sterility testing at <Redacted B4> prior to release. However, not all sterile drug products are tested to ensure they are pyrogen-free. For example:
I. Dexamethasone 400mcg/0.l Injection, Lot #: 201804091 was not tested for endotoxin prior to distribution.
2. Lidocaine 1 %/Phenylephrine 1.5% Solution PF, Lot#: 201806111 was not tested for endotoxin prior to distribution.
(This is a repeat observation from a previous inspection).
Observation 6
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically,
Your firm does not conduct potency testing for any finished drug products prior to distribution. For example:
1) Ephedrine sulfate 5mg/mL lnjection-5mL Syringe, Lot#: 201810191 & Lot#: 201903132 was distributed without potency data.
2) Methylcobalamin 5mg/mL Injection Solution MDV, Lot#: 201901312 was distributed without potency data.
3) Dexpanthenol 250mg/mL Injection Solution MDV, Lot#: 201902012 was distributed without potency data.
(This is a repeat observation from a previous inspection).
Observation 7
Written records are not always made of investigations into unexplained discrepancies.
Specifically,
You firm has not established alert levels or initiated investigations into repeated microbial incursions into the ISO5 classi tied zone. From l I /30/2017-05/13/20 19 approximately 15 microbial incursions were reported in your 1SO5 LAFH. No action was taken until 12/05/2018 with the initiation of CAP A Report#: 20 l 8-00 l. Incursions into the 1SO5 LAFH continued after completion of the investigation conducted for CAPA Report #: 2018-00 l, for example:
I) 03/01/2019 touch plate positive for growth.
2) 05/13/2019 touch plate positive for growth.
No follow up investigations have been conducted to determine the cause of continued microbial incursions into the 1SO5 LAFl-J.
Inspection Feb 7, 2017: 13 observations
- Firm on the cover
- , 1125 Hollipark Drive CIT Y, STATE AND ZIP CODE RAM Pharma, Inc. -----------------+------~----------- ------, Idaho Falls, ID 83401
- FEI number
- 3012465222
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 22215 26th Ave. SE. Suite 210 Bothell, WA 98201
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written or followed. Specifically,
A) An ATRIX VACOMEGASCT ESD 1 gallon vacuum was observed in use by the operator to vacuum the floor of the ISO 7 Cleanroom prior to the production of sterile drug Eylea 2mg/0.05mL injection, lot 201702081 on 2/8/17. Your SOP 05-00 1 Clean Suite Cleaning and Sanitizing Operation requires that yo u "*** Use HEPA v acuum to clean floors" for daily cleaning.
B) Media fills for the production operator were not performed prior to conducting sterile drug production of the first batch of sterile drug product on 7/26/16. From 7/26/16 to 2/8/17, 105 batches were produced without media fills being performed for the production operator according to the assigned schedule outlined in the following SOPs:
1)SOP 08-006 Personnel Monitoring - High-Risk Media Fill requires that "*** Each person authorized to c ompound high-risk level CSP's must perform this procedure semiannually."
2) SOP 08-007 Personnel Monitoring - Low-Risk Media Fill requires that "*** Persons authorized to compound must perform this procedure at least once annually." ...
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically,
A) Your environmental monitoring (EM) procedure SOP 08-004 Environmental Monitoring - Microbial is deficient in that it states to "*** Perform surface sampling in al l ISO classified area on a periodic basis." In addition, you are not performing EM according to the following methodologies and frequencies as you currently r ely on EM to be performed by a third-party certifier every six months:
1) Viable air sampling is not performed in the Baker EG-4320, S/N 55304 ISO 5 horizontal laminar flow hood ( LFH) when sterile drug products are produced.
2) Surface sampling for microbiological monitoring is not performed in the Baker EG-4320, S/N 55304 ISO 5 h orizontal LFH when sterile drug products are produced.
3) Personnel monitoring is not conducted of production operators at least daily when sterile drug products are p roduced.
4) Non-viable air sampling is not performed in the Baker EG-4320, S/N 55304 ISO 5 horizontal LFH and adjacent ISO-classified areas when sterile drug products are produced. ...
Observation 3
conditions. Specifically, during the production ofEylea 2mg/0.05mL injection, lot 201702081 conducted on 2/8/17:
A)A piece of apparent exposed particle board measuring approximately three-quarter inches thick, 44 inches w ide, and at least six inches deep was observed through the front edge guard vent of the Baker EG-4320, S/N 5 5304 ISO 5 horizontal LFH in the ISO 7 Cleanroom. The apparent particle board was observed seated on two metal u-channels and adhered to the underside of the metal workbench of the ISO 5 horizontal LFH.
B) Two pieces of apparent plastic were observed missing from a frame installed between the ceiling and metal H EPA filter grate of the Baker EG-4320, S/N 55304 ISO 5 horizontal LFH which exposed a groove that appears to not be smooth or easily cleanable.
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment t o produce aseptic conditions. Specifically,
A) Your firm uses non-sterile, low-shedding wipes sprayed with sterile 70% isopropyl alcohol (IPA) to clean and w ipe down the metal HEPA filter grate and metal workbench of the ISO 5 horizontal LFH prior to sterile drug pr oduction. This practice was observed on 2/8/17.
B)You are not following your SOP 05-003 Aseptic Technique and Related Practices Assessment of Compounding P ersonnel which states in part "*** Disinfects components/vials with an appropriate agent prior to placing into ISO Class 5 work area." For example, drug containers, components, closures and equipment used in the production of Eylea 2mg/0.05mL injection, lot 201702081 on 2/8/17 were placed into the Baker EG-4320, S/N 55304 ISO 5 horizontal LFH without first disinfecting the outer surface.
C) The Accel TB wipes used for wiping down the metal bench and interior of the pass-through in the ISO 8 Gowning Room and Accel TB Ready to Use Liquid used in the ISO 7 Cleanroom is not sterile and it is not a sporicidal agent. ...
Observation 5
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not i nclude adequate validation of the sterilization process. Specifically,
A) The Tuttnauer Brinkmann 2340E, S/N 2106804 autoclave has not been validated to confirm effective sterilization through the designated sterilization time and temperature cycle of seven minutes at 273 degrees Fahrenh eit (134 degrees Celsius) for the syringe capper/de-capper device used in sterile drug production. Biological indic ators are also not used during this sterilization process.
B) The production process of using a non-sterile hemostat for handling a sterile dropper bottle in the ISO 5 horizontal LFH without adequate sterilization of the hemostat has not been validated to ensure sterility of the finished sterile ophthalmic products: Vigamox lot 201609202; Phenylephrine Hydrochloride Ophthalmic Solution lot 201609272; Neomycin/Polymyxin B Sulfates/Dexamethasone Ophthalmic Suspension lot 201610051; and Tob ramycin/Dexamethasone Ophthalmic Suspension lot 201610052. ...
Observation 6
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine c onformance to such requirements. Specifically,
A) Sterility testing was not performed on each finished or representative finished batches for 20 of 23 drug products produced since 7/26/16 that are purported to be sterile. For example, sterility testing was not performed on the following sterile drug products:Sterility testing was not performed on each finished or representative finished batches for 20 of 23 drug products produced since 7/26/16 that are purported to be sterile. For example, sterility testing was not performed on the following sterily drug products:
1) Vigamox, beyond use date (BUD) of 1 mo nth ambient, lot 201609202.
2)Phenylephrine Hydrochloride Opthalmic Solution; unknown BUD, lot 201609272.
3)Neomycin/polymyxin B Sulfates/Dexamethasone Opthalmic Suspension BUD of 30 days ambient, lot 20 1610051.
4) Tobramycin/Dexamethasone Opthalmic Suspension BUD of 30 days ambient, l ot 201610052. ...
Observation 7
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release. Specifically,
A) Potency testing is not performed for each batch of finished sterile and non-sterile drug products produced prior to release. For example:Potency testing is not performed for each batch of finished sterile and non-sterile drug products produced prior to release. For example:
1) The following sterile drug products:
a) Lidocaine 1%/Phenylephrine 1.5% injection; BUD of 66 days ambient for lots 201609231, 201610061, 201 610201, 201611301 and 201702021.
b) Lidocaine 7.5mg/mL/Epinephrine 0.25mg/mL injection; BUD of 45 days frozen for lots 201611181 and 201701061.
2)The following non-sterile drug products:
a) Lidocaine/Epinephrine/Tetracaine (LET) topical gel BUD of "150 days refrigerated; 21 days room temperature" for lots 201612222 and 201701171.
b) Lidocaine/Prilocaine/Tetracaine/Phenylephrine (TAP) topical gel BUD of 90 days ambient for lot 201612221. ...
Observation 8
There is not written testing program designed to assess the stability characteristics of drug products. Specifically,
A) Your SOP 12-004 Determination of Beyond Use Dating is deficient in that it does not describe tests that evaulate the sterility and potency for the BUD claimed. For example, stability testing has not been performed for the following sterile drugs:
1)Lidocaine 1 %/Phenylephrine 1.5% injection formulated from non-sterile components; BUD of 66 days ambient fo r lots 201609231, 201610061, 201610201, 201611301 and 20 1702021.
2)Sterile drugs repackaged in the LFH:
a)Phenylephrine Hydrochloride Opthalmic Solution 2.5%; BUD is unknown for lot 201609272.
b)Tobramycin/Dexamethasone Opthalmic Suspension: BUD of 30 days ambient for lot 201610052.
c)Vigamox; BUD of 30 days ambient for lot 201609202.
d) Neomycin/Polymyxin B Sulfates/Dexamethasone Opthalmic Suspension; BUD of 30 days ambient for lot 2 01610051.
3)Oxytocin 30U/500mL NS intravenous solution; BUD of 6wks ambient, lots 201611082, 201611112, 2016 11291, 201612151, 201701041, 201701111, and 201701241.
B)The BUD of sterile drug products exceeded the expiry date of a raw material component used in production. ...
Observation 9
Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the duties they perform. Specifically,
A)The following attire worn by the operator on 2/8/17 during the production of Eylea 2mg/0.05mL injection, lot 2 01702081 i n the Baker EG-4320, S/N 55304 ISO 5 horizontal LFH was inadequate as follows:
1) Non-sterile boot covers, non-sterile coveralls, non-sterile hair cover, non-sterile surgical mask, and protective e yewear that had not been previously disinfected prior, that were observed worn during sterile drug production.
2) The hood of the non-sterile coverall and non-sterile surgical mask worn did not provide adequate coverage of t he forehead, cheeks, and chin of the operator during sterile drug production.
B)An ATRIX VACOMEGASCT ESD 1 gallon vacuum and its power cord, attachments and hose were observed i n direct contact with a non-sterile coverall worn by the operator in the ISO 7 Cleanroom during vacuuming of the f loor. ...
Observation 10
There is no quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products. Specifically,
A) There is no procedure for the release of finished drug products.
1)Your current practice for the release of sterile filtered drugs are subject to an in-house Day 4 sterility test; h owever, there are no records to show quality control unit review of such records and no documentation of the date you distributed these sterile filtered drugs:
a) Lidocaine 1%/Phenylephrine 1.5% injection lots 201609231, 201610061, 201610201, 201611301 and 2017 02021.
b) Lidocaine 7.5mg/mL/Epinephrine 0.25mg/mL injection lots 201611181 and 201701061.
2) You do not have a production batch record for Lidocaine 4%/Epinephrine 0.05%/ Tetracaine 0.5% (LET) Topical Gel, lot 201612031 that was produced on 12/3/16. RAM Pharma, Inc. Invoice no . 1055 dated 12/5/16 documented the sale and distribution of 10/3mL LET Gel syringes from this lot.
B) There is no procedure for the review of production batch and control records. ...
Observation 11
Routine calibration of electronic equipment is not performed according to a written program designed to assure proper performance. Specifically,
proper performance. Specifically,
A) The digital balance used in the weighing of raw material components for production, namely Torbal AGZN100 ba lance, 10 0g capacity; A&D FJ-123 balance, 120 g capacity; and Ohaus Scout Pro balance, 400g capacity have not been calibrated. The calibration weights that are available for use are also not calibrated.
B)The digital thermometers used to monitor temperatures of the refrigerator in the "2 Incoming Release" room; a nd the refrigerator and freezer in the "8 Shipping" room have not been calibrated.
Observation 12
The labels of your outsourcing facility's drug products do not include information required by sections 503B9a) ( 10) (A) and (B). Specifically,
The following information is not found on some of your drug product labels:
A)Product labels consisting of the statement "Compounded Drug" are deficient in that it does not include the statements "This is a compounded drug", quantity or volume, and inactive ingredients. Examples of drug products that do not contain this information are:
1)Ceftazidime 2250mcg/0.1 mL
2)Dexamethasone Sodium Phosphate 400mcg/0.05mL.
3)Phenylephrine Hydrochloride 2.5mg/mL s olution
4) Vancomycin Hydrochloride 1000mcg/0.1mL
B) A list of active and inactive ingredients, identified by established name and the quantity or proportion of each i
1)Drug product Lidocaine 4% Epinephrine 0.05% Tetracaine 0.5% topical gel is identified on the product label as " LET Gel 4% 0.05% 0.05% TOPICAL GEL".
2) Drug product Lidocaine 10% Prilocaine 10% Tetracaine 4% Phenylephrine 2% dental gel is identified on the pr oduct label as "TAP Gel 10 % 10% 4% 2% DENTAL GEL". ...
Observation 13
The drug product report your outsourcing facility submitted to the FDA as required as by section 503B (b) (2) ( A) is not accurate. Specifically,
You underreported 6 units of Vancomycin 1000mcg/0.1 mL syringe and 6 units of Ceftazidime 2250mcg/0.1mL syringe in the drug product report your outsourcing facility submitted to the FDA on 12/28/16 for drugs produced during the previous six months through 11/30/16.
* Inspection Dates: 2/7/2017, 2/8/2017, 2/9/2017, 2/10/2017, 2/13/2017, 2/15/2017, 3/1/2017.
State board of pharmacy records
State board of pharmacy records for Idaho are not checked: the board’s former web address (bop.idaho.gov) did not respond on November 6, 2026, and no longer resolved when tried again on November 7, 2026; the board’s pages now sit on the Division of Occupational and Professional Licenses site, which this index has not yet read.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054022133 | LICENSED PHARMACY | COMPOUND PREFERRED LLC | IDAHO FALLS, ID | CLOSED |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Illinois Department of Financial and Professional Regulation license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.